Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

ICSR in Pharmacovigilance in 2026: Case Processing, E2B(R3), Reporting Timelines, and Compliance Guide

Explore how safety teams manage ICSR validity, day zero, MedDRA coding, seriousness assessment, E2B(R3) reporting, follow-up, and duplicate cases. This guide also explains reporting timelines, inspection evidence, and the controls needed for reliable pharmacovigilance compliance.
  • Blog, Quality Management System
Pharmacovigilance dashboard showing ICSR validity criteria, seriousness assessment, duplicate case management, reporting timelines, and EudraVigilance submission controls.

Pharmacovigilance System Master File in 2026: PSMF Requirements, EU GVP Module II, QPPV, and Inspection Readiness

Explore PSMF requirements, structure, maintenance, and inspection readiness under EU GVP Module II. This article explains QPPV responsibilities, annex control, computerised systems, audit evidence, and change management practices that help drug safety teams prepare for regulatory inspections.
  • Blog, Quality Management System
PSMF structure showing QPPV responsibilities, safety data systems, PSMF annexes, quality controls, audits, and inspection-ready documentation.

Pharma Quality Systems in 2026: ICH Q10, GMP Compliance, and PQS Guide

Discover how pharma quality systems based on ICH Q10 strengthen GMP compliance through CAPA, change management, quality risk management, and management review. Learn how an effective pharmaceutical quality system improves inspection readiness, prevents recurring failures, and supports continual improvement.
  • Blog, Quality Management System
Pharmaceutical quality management system infographic showing ICH Q10 elements, CAPA system, quality risk management, and GMP quality controls in pharma manufacturing.

Risk Management Plan in Pharmacovigilance in 2026: EMA RMP and Safety Monitoring Guide

This guide explains how an EMA risk management plan supports safety specification, additional pharmacovigilance activities, and effective risk minimisation measures. It also shows how lifecycle updates help teams manage important identified risks and maintain a positive benefit-risk balance.
  • Blog, Quality Management System
Illustration of an EU risk management plan showing safety specification, important identified risks, lifecycle monitoring, and additional pharmacovigilance activities.

Rechallenge in Pharmacovigilance in 2026: Causality Assessment and Drug Safety

This article explains how positive and negative drug rechallenge findings strengthen causality assessment, improve Individual Case Safety Report documentation, and support regulatory decision-making under WHO-UMC, Naranjo, EMA GVP Module VI, and ICH E2D frameworks worldwide.
  • Blog, Quality Management System
Drug safety specialist reviewing positive and negative rechallenge outcomes, adverse drug reaction data, and Individual Case Safety Report documentation.

Dechallenge in Pharmacovigilance in 2026: Causality Assessment and Safety Signal Review

Explore how dechallenge in pharmacovigilance supports causality assessment, safety signal review, and regulatory reporting. Learn how positive dechallenge, negative dechallenge, and rechallenge findings help pharmaceutical teams evaluate adverse drug reactions and improve Individual Case Safety Reports.
  • Blog, Quality Management System
Pharmacovigilance causality assessment workflow showing adverse drug reaction evaluation, dechallenge outcomes, and Individual Case Safety Report review

Good Manufacturing Practice in UK in 2026: MHRA GMP Inspection Guide

Learn how good manufacturing practice in UK supports successful MHRA inspections through risk-based quality systems, data integrity, validation, and effective CAPA. Discover the latest UK GMP expectations and practical strategies to improve inspection readiness and long-term regulatory compliance.
  • Blog, Quality Management System
Pharmaceutical manufacturing UK facility prepared for MHRA GMP inspection with cleanroom operations, quality management, and GMP compliance controls.

Good Manufacturing Practices in Malaysia in 2026: NPRA GMP Inspection Guide

Learn how Malaysia GMP guidelines and NPRA GMP inspections align with PIC/S GMP requirements. This guide explains pharmaceutical quality systems, inspection priorities, common findings, CAPA expectations, and practical strategies to improve GMP compliance and inspection readiness.
  • Blog, Quality Management System
NPRA GMP inspection in a pharmaceutical manufacturing Malaysia facility following PIC/S GMP requirements and pharmaceutical quality system standards

Good Manufacturing Practices in Australia in 2026: TGA GMP Inspection Guide

Understand how TGA GMP inspections work in Australia, explore official GMP guidance PDFs, review common inspection findings, and use a practical GMP compliance checklist to strengthen pharmaceutical quality systems and improve inspection readiness before your next regulatory audit.
  • Blog, Quality Management System
Illustration of a pharmaceutical manufacturing facility showing TGA GMP inspection activities, pharmaceutical quality system controls, and GMP inspection readiness based on Australia GMP guidelines.

Good Manufacturing Practices in Canada in 2026: Health Canada GMP Inspection Guide

Learn how Health Canada GMP inspections evaluate pharmaceutical manufacturers, explore official guidance documents, review common inspection findings, and use practical checklists to strengthen compliance and prepare for successful Drug Establishment Licence inspections.
  • Blog, Quality Management System
Pharmaceutical quality specialist reviewing manufacturing compliance during a Health Canada inspection, illustrating GMP in Canada, GUI 0001 requirements, and Drug Establishment Licence Canada readiness.